

Index

- AAP (American Academy of Pediatrics), 48, 57
 Abbott Laboratories Fund, 277
 abortion policies
 stem cell research and, 20
 Abrams, Thomas, 129, 130
 absorption, distribution, metabolism and elimination studies. *See* ADME
 Academy of Managed Care Pharmacy.
 See AMCP
 acetylsalicylic acid, 151. *See also* aspirin
 Acquired Immune Deficiency Syndrome.
 See HIV/AIDS
 Act-Up New York, 306
 ADAP (AIDS Drug Assistance Program), 310, 311
Additional Safeguards for Children in Research, 57, 58, 59
 “adequate provision,” 157
 ADME studies (absorption, distribution, metabolism and elimination), 48, 56
 genetics and, 83
 Administrative Procedure Act. *See* APA
 adverse event reporting system. *See* AERS
 advertising, 3
 DTCA, 127
 reminder, 156–157
 AERS (adverse event reporting system), 55
 FDA and, 54
 Africa
 AZT in, 273–274
 HIV/AIDS in, 28, 273, 339, 347–348
 Africa, sub-Saharan
 HIV/AIDS in, 273, 452
 IP rights in, 346
 African Americans
 antidepressants and, 80
 clinical testing and, 93
 health literacy for, 88
 high blood pressure among, 84
 pain medications for, 80
 race-based drug therapies for, 94
 smoking and, 86
 Tuskegee syphilis study and, 19, 101
 Africans
 alternative treatments for, 90
 AIDS activism (medical), 15, 301–308
 Act-Up New York, 306
 ATAC, 307, 316
 collaboration in, 308–311
 community involvement for, 308
 conflicts of interest and, 316–318
 ETAG, 307
 in EU, 307
 FDA approval and, 308, 312–314
 FPC and, 311
 NIH and, 308
 pharmaceutical industry funding for, 318
 Project Inform, 306
 AIDS Drug Assistance Program. *See* ADAP
 AIDS Treatment Activists Coalition. *See* ATAC
 Altbach, Philip, 267

- alternative treatment(s)
 for Africans, 90
 for Asians, 90
 for minorities, 90
 Alzheimer's Disease, 20
 AMA (American Medical Association),
 77, 133
 AMCP (Academy of Managed Care
 Pharmacy), 238
 American Academy of Pediatrics. *See*
 AAP
 American College of Physicians, 145
 medication recommendations by, 145
 American Society for Reproductive
 Medicine, 116
 Annan, Kofi, 349
 anthrax
 Cipro and, 268
 in US, 267
 antibiotics
 risk-benefit ratios for, 137
 antidepressants, 13, 77
 African Americans and, 80
 Ashkenazi Jews and, 85
 for children, 54
 fluoxetine, 76
 GSK research for, 77
 Hispanic Americans and, 80, 84
 paroxetine, 76
 SSRI v., 219, 287
 suicidal ideation from, 77
 venlafaxine, 77
 antiretrovirals
 in Gillespie-White/Attaran study, 344
 in Kenya, 347
 in Norway, 347
 pricing patterns for, East Africa,
 346–347
 in Tanzania, 347
 antiviral drugs. *See* drugs, antiviral
 AP (Associated Press)
 Tuskegee syphilis study and, 101
 APA (Administrative Procedure Act)
 drug regulations and, 116
 ART (assisted reproductive technology)
 Fertility Clinic Success Rate and
 Certification Act and, 115
 processes for, 116
 stem cell research and, 115
 Asia
 HIV/AIDS in, 28
 Asians, 84
 alternative treatments for, 90
 belief systems for, 89
 aspirin, 150–152
 Bayer and, 151
 development of, 151
 medicinal properties, 151
 assisted reproductive technology. *See*
 ART
 ATAC (AIDS Treatment Activists
 Coalition), 307, 316
 Attaran, Amir, 343
 Australia
 cost guidelines in (new drugs), 237
 stem cell research in, 120
 Austria
 stem cell research in, 119
 Axios Foundation, 277
 AZT
 in Africa, 273–274
 HIV/AIDS and, 270, 302, 304
 NIH and, 270
 side effects of, 303
 Bale, Harvey, 265
 Baltimore Lead Abatement Study,
 72
 Bardes, Charles, 131
 Barshefsky, Charlene, 340
 Bayer, 151–152
 aspirin and, 151
 Farbe, IG, and, 151
 Prontosil development at, 27
 belief system(s)
 for Asians, 89
 for Hispanic Americans, 89
 informed consent and, 103
 Best Pharmaceutical for Children Act.
See BPCA
 Best Pharmaceuticals for Children Act of
 2002, 18
 beta blockers, 143
 Tenormin, 143
 Toprol XL, 143
 Bidil
 nitric oxide deficiency and, 95
 race-based drug therapies and, 95
 Bill and Melinda Gates Foundation, 11,
 358, 367, 391
 endowment for, 33
 HIV/AIDS research and, 35

- multiple perspectives system and, 277
- tropical disease research and, 33
- biochemistry
 - pharmacology and, 149–150
- Biologics Control Act, 49
- biotech industries. *See* industries, biotech
- “black box” labels
 - FDA and, 13
- “blockbuster” drugs, 29, 328–329
- Boston Globe*, 219
- Botswana
 - HIV/AIDS in, 277, 279
- BPICA (Best Pharmaceutical for Children Act), 50, 51, 69, 77
 - IOM and, 69
 - on pharmacovigilance, 54
- Brave New World* (Huxley), 115
- Brazil
 - IP rights in, 268
- Brenner v. Manson*, 337
- “brief summary”
 - in reminder advertisements, 156
- Broder, David, 375
- bupropion, 86
- Burroughs, Valentine, 17, 19, 103, 376, 394
- Bush, George W, 112, 117, 119
- “business stealing”
 - drug sales and, 173
- Campbell, William C, 11
- Canada
 - drug price controls in, 327
 - stem cell research in, 120
- cancer. *See* therapies, cancer
- Carter, Jimmy, 389
- CDC (Centers for Disease Control), 391
- Central Hudson Gas & Electric Corp. v. Public Service Commission of New York*, 188, 189
- CFR (Code of Federal Regulations)
 - Additional Safeguards for Children in Research* in, 57, 58
 - on pediatric research, 57, 59
- chemotherapy, 26
- dyes and, 26
- Childhood Immunization Initiative, 256
- children. *See also* pediatrics; research, pediatric
 - antidepressants for, 54
 - clinical research and, 17–18
 - informed consent for, 43–44
 - SSRI and, 396
 - Thalidomide and, 17
 - vaccines for, 231–232, 355, 446
- China
 - informed consent in, 44
 - IP rights in, 267
 - stem cell research in, 120
- Chloramphenicol, 49
- CIOMS (Council for the International Organizations of Medical Sciences), 17, 37
 - International Ethical Guidelines for Biomedical Research Involving Human Subjects, 37, 41, 42
 - “minimal risks” guidelines, 71, 73
 - on pediatric research, 57, 68
- Cipro
 - anthrax and, 268
 - Bayer and, 268
- Clarinex
 - Claritin v., 142
 - Claritin, 141, 142
 - Clarinex v., 142
- Clean Air Act (US), 114
- Clemente, CL, 264
- clinical equipoise, 62–63, 74
- Clinical Investigation of Medicinal Products in the Pediatric Population*, 58, 59
- clinical research. *See* research, clinical
- clinical studies. *See* trials, clinical
- clinical trials. *See* trials, clinical
- Clinton, Bill, 340, 347
- cloning, 114–116
 - in France, legal limits, 119
 - Human Cloning Prohibition Act, 113
 - reproductive, 111
 - SCNT, 110, 111
 - in South Korea, legal limits, 120
 - US government restrictions on, 118
- Code of Federal Regulations. *See* CFR
- Collaborating Centers for Influenza, 353
- Commercial Speech Doctrine, 188, 438
- WLF and, 189–190
- common indications. *See* diseases, common
- comparator products, 46
- “compassionate use” programs
 - for HIV/AIDS research, 25
- Competitive Media Reporting, 177

- Consumer-Directed Broadcast Advertisements*, 157
 DTCA and, 157
Contract With America, 114
 controlled substances
 DEA and, 146
 general medications and, 146
 costs, drug
 controls for, 133–134
 for regulation, 15
 costs, research, 27–28
 development costs for, 27
 Council for the International Organizations of Medical Sciences.
 See CIOMS
 Crooks, Glenna, 19
 “cultural competency,” 88
 cultural practices
 belief systems as part of, 89
 individualized therapies and, 89–91
- Daniels, Norman, 135
 Danzis, Scott, 132
 data monitoring committee. *See* DMC
 DCT (direct-to-consumer) Promotion, 165
 DEA (Drug Enforcement Agency), 146
 Declaration of Helsinki. *See* Helsinki Declaration of Ethical Principles for Medical Research Involving Human Subjects
 “Declaration on Universal Norms on Bioethics,” 41
 Delaney, Martin, 104, 253, 397
 detailing. *See* physician detailing
 Detmer, Donald, 130
 diabetes mellitus, 84
 Dickey Amendment (US)
 HHS and, 117
 stem cell research and, 111, 121
 didanosine
 in clinical trials, 304
 FDA approval for, 305
 for HIV/AIDS, 303
 diets. *See* nutrition
 “direct benefit”
 EU Directive on Clinical Trials and, 73
 in pediatric research, 73–74
 direct-to-consumer promotions. *See* DTC (direct-to-consumer) promotions
 Dirksen, Everett, 240
 diseases, common
 clinical research for, 28
 diseases, rare
 clinical research for, 29
 occurrence rates for, definition, 30
 “Orphan Drug Law” and, 30
 diseases, tropical, 28
 Bill and Melinda Gates Foundation and, 33
 foundations for, 31–33
 The Global Fund to fight AIDS, Tuberculosis and Malaria and, 32
 suggested funding for, by nation, 31
 WHO and, 31
 diseasification, 149
 DMC (data monitoring committee), 62
 Doctors’ Trial, 38
 “Dodge Ball Vioxx,” 14
 Doha Declaration on TRIPS and Public Health, 258, 338, 342, 350, 459
 Dolder-Club-Meetings, 32
 Domagk, Gerhard, 27
 Donohue, Julie, 129
 dosing, drugs
 under ethical templates, 221–222
 in individualized therapies, 94
 “off-label” use for, 69, 132
 pediatric calculations for, 48
 in pediatric research, 52–53
 double-blind trials, 24
 scientific ethics and, 23
 Drews, Jürgen, 10, 11
 drug dosing. *See* dosing, drugs
 Drug Enforcement Agency. *See* DEA
 drug labeling. *See* labeling, drugs
 drug licensing. *See* licensing, drugs
 drug pricing. *See* pricing, drugs
 drug recalls. *See* recalls, drug
 drug research. *See* research, clinical
 drug safety. *See* safety, drugs
 drug sales. *See* sales, drug
 drugs, antiviral
 for influenza, 354
 drugs, “blockbuster,” 29, 328–329
 drugs, fixed-dose combination
 clinical trials for, 38
 as treatment option, 38
 drugs, “lifestyle,” 127, 253. *See also* drugs, prescription
 MUSE, 163

- drugs, new, 186, 235
 in Australia, cost guidelines for, 237
 “blockbuster,” 29, 328–329
 clinical trials for, 38
 cost-effectiveness of, 231–236
 development costs for, 27, 252, 311–312
 government reimbursement for (in US), 288–289
 for HIV/AIDS, 253
 misbranding, 185–186
 older v., 142–143
 in UK, cost guidelines for, 238
 in UK, launches for, 25
 in US, 25
- drugs, prescription, 136–145
 disadvantages of, 143
 DTCA and, sales from, 173
 FDA and, 155
 fixed-dose combination of, 38
 for hypertension, 139
 “lifestyle,” 127
 marketing for, 153–154, 170
 MUSE, 163
 OxyContin, 162–163
 “Patient Package Inserts” for, 155
 pharmaceutical industry and, 3
 Prograf, 164
 risk-benefit ratios for, 137
 sales figures for (2003), 153, 174
 Viagra, 213, 217–219
- DTC (direct-to-consumer) promotions, 165
- DTCA (direct-to-consumer-advertising), 127, 131, 154, 169, 170–172, 366. *See also* advertising
 “adequate provision” as part of, 157
 Competitive Media Reporting and, 177
 consumer involvement in, 171–172
Consumer-Directed Broadcast Advertisements and, 157
 educational value of, 178–179
 in EU, 202
 expenditures for, 17, 127
 Fairness Doctrine and, 182
 FDA and, 128, 129, 170
 financing arrangements for, adjustments, 182–183
 general medication use and, influence on, 144, 175–176
 government policy alternatives to, 180–183
 for “lifestyle” drugs, 127
 literature on, 179
 long-term influence of, 172–173, 181
 National Ambulatory Medical Care Survey and, 177
 objectives of, 128, 153–154, 170
 patient information and, 202
 patient treatment and, influence on, 169, 176–177, 182
 patient-physician relations and, influence on, 170
 physician detailing and, 128
 physicians’ visits and, influence on, 175
 prescription drug sales and, 173
 print advertisements for, 156
 public health care and, 128–131, 169–170, 179
 reminder ads and, 156–157
 Rogaine and, 171
 surveys for, 153, 172, 173–175, 177
 television and, 156
 treatment therapies and, influence on, 170, 177–178
 types of, 156
- Dunn, Belynda, 206
- Dworkin, Ronald, 279
- The Economist*, 235
- “Effects of a Single Dose of Dextroamphetamine in Attention Deficit Hyperactivity Disorder: A Functional Magnetic Resonance Study,” 61
- EG (embryonic germ) cells, 121. *See also* stem cells
- Eisenberg, Rebecca S, 269
- Eli Lilly & Company, 77, 255, 334
 Elizabeth Arden and, 334
 Elizabeth Arden, 334
 embryonic germ cells. *See* EG
 embryonic stem cells. *See* ES
- EMA (European Medicines Agency) PC and, 70
- Energy Security Act (US), 114
- Enola beans
 patents for, 266
 Proctor, Larry, and, 266
- ES (embryonic stem) cells, 110, 121. *See also* research, stem cell; stem cells
- ETAG (European Treatment Activist Group), 307

Cambridge University Press

0521854962 - Ethics and the Pharmaceutical Industry

Edited by Michael A. Santoro and Thomas M. Gorrie

Index

[More information](#)

476

“Ethical Considerations in HIV Preventive Vaccine Research,” 40

ethical templates, 216–222

- cost advantage constraints within, 214–215
- cost-worthiness as part of, 214
- coverage decision hierarchy within, 211–212
- deliberations under, 216
- drug dosage under, 221–222
- effectiveness of treatment as part of, 214
- elements of, 210
- generic rationales for, 212–215
- for pharmacy benefit management, 209–222
- SSRI under, 219–221
- Viagra under, 217–219

ethics, 21–26. *See also* ethical templates; ethics, corporate; ethics, Hippocratic; ethics, medical; ethics, scientific

- business, 396
- in clinical research, 9, 38–41
- governments and, 109
- Hippocratic, 36
- in pediatric research, 56–62
- review committees, 45

“Ethics and Clinical Research,” 413

ethics, corporate

- medical ethics v., 29
- pharmacy benefit management and, 209–222

ethics, Hippocratic, 36. *See also* ethics, medical; Hippocratic Oath

ethics, medical, 21–24, 26

- in clinical research, 36
- corporate ethics v., 29
- drug therapy under, 22
- Hippocratic Oath as part of, 22

ethics, scientific, 21–26

- in clinical research, 36
- data disclosure as part of, 23
- double-blind trials and, 23
- experimental reproducibility and, 23
- “non-scientific” v., 23

ethnicity. *See also* minorities

- cross-racial variability and, 83
- definitions for, 82

Index

EU (European Union)

- drug price controls in, 327
- DTCA in, 202
- FP6 in, 119
- stem cell research policy within, 118

EU Directive on Clinical Trials, 37, 70

- “direct benefit” and, 73
- funding sponsor obligations for, 45
- patient selection and, 70
- pediatric research and, 68

European Treatment Activist Group. *See* ETAG

“expanded access” programs

- for HIV/AIDS research, 25

Fair Access to Clinical Trials Act, 78

Fair Pricing Coalition. *See* FPC

Fairness Doctrine, 182

False Claims Act. *See* FCA

Farbe, IG, 151

Fauci, Anthony, 354

FCA (False Claims Act), 132, 185, 193

- “double falsehood” requirements for, 192
- Frankin v. Parke-Davis* and, 191–193, 194
- “off-label” usage under, 191
- “qui tam” suits under, 191

FDA (Food and Drug Administration), 69, 93, 117, 393

- AERS and, 54
- AIDS activism and, 308, 312–314
- “black box” warning labels from, 13
- clinical testing and, 92
- Consumer-Directed Broadcast Advertisements* and, 157
- didanosine and, approval of, 305
- drug promotion violations and, 162–164
- DTCA and, 128, 129, 170
- FDCA and, 159, 184
- generic v. brand name medications and, 140
- genomic research and, 295
- labeling regulations by, 49, 438
- manipulation of, 314–315
- Modernization Act of 1997 for, 18
- MUSE and, 163
- Office of Pediatric Therapeutics and, 69

- “off-label” usage approval by, 187, 193
 OTCs and, specifications, 141–142
 pediatric research and, 48
 PREA and, 69
 prescription drugs and, 155
 race-based drug therapies and, 95
 risk management and, 285
 statutory limitations for, 51
 vaccines and, 256
 Viagra and, approval for, 217
 Vioxx and, 16
 WLF and, 189, 190
 FDAMA (Food and Drug Administration Modernization Act), 50, 190, 439
 FDCA (Food, Drug and Cosmetic Act), 12, 49, 98, 393
 FDA and, 159, 184
 Kefauver-Harris Amendments to, 49
 labeling under, 186–187
 misbranding under, 161, 184
 “off-label” promotions under, 185, 187
 promotional development under, 166, 167
 promotional regulation under, 159
 usage directions under, for labels, 186
Federal Register, 117
 Female Health Company, 277
 Fen-Phen, 13
 Fertility Clinic Success Rate and Certification Act, 115
 FET (frozen embryo transfer), 428
 First Amendment (US Constitution)
 Commercial Speech Doctrine as part of, 188, 438
 drug promotions under, 184
 “off-label” promotion under, 188–191, 193
 WLF and, 190–191
 fixed-dose combination drugs
 clinical trials for, 38
 as treatment option, 38
 flouxetine, 76
 Fluss, Sev S, 17, 57
 Foege, Bill, 358, 367
 Food and Drug Administration. *See* FDA
 Food and Drug Administration Modernization Act. *See* FDAMA
 Food, Drug and Cosmetic Act of 1934. *See* FDCA
 Foreign Assistance Act (US), 114
 formularies
 insurance and, 147
 third party payer systems and, 147
 Forum for Collaborative HIV Research, 298
 foundations
 Bill and Melinda Gates Foundation, 11
 FP6 (sixth research framework program), 119
 in EU, 119
 FPC (Fair Pricing Coalition), 311
 France
 cloning limits in, 119
 innovation output in, 333–334
 stem cell research in, 119
 Francis, Tommy, 386
 Franklin, Ben, 378
Franklin v. Parke-Davis
 FCA and, 191–193, 194
 “off-label” promotion and, 191
 Frazier, Kenneth, 14
 frozen embryo transfer. *See* FET
 funding source(s)
 for AIDS activism, 318
 for clinical trials, 45–46, 322–324
 EU Directive on Clinical Trials and, 45
 foundations as, 322
 GCP guidelines for, 45
 governments, 322
 ICH and, 45
 for multiple perspectives systems, 277
 pharmaceutical industry as, 323
 responsibilities of, 46
 for tropical diseases, by nation, 31
 WHO and, 45
 Gallup polls, 4
 gamete intrafallopian transfer. *See* GIFT
 Garber, Alan, 246
 Gathii, James, 259, 379
 GCP (Guidelines for Good Clinical Practice for Trials on Pharmaceutical Products)
 funding sponsor obligations for, 45
 patient selection and, 70
 WHO and, 37, 40, 43

- genetics
 ADME and, 83
 Human Genome Project and, 83
 within individualized therapies, 83–85
 pharmacodynamic properties and, 83
 pharmacogenetics, 83
 research, 91–92
 variations within, 82
- genomic research. *See* research, genomic
- Genomic Research in the African
 Diaspora Biobank. *See* GRAD
- Germany
 innovation output in, 333
 stem cell research in, 119
- GIFT (gamete intrafallopian transfer),
 428
- Gillespie-White, Lee, 343, 459–460
- Gillespie-White/Attaran study, 343–344,
 348, 459
 antiretroviral access in, 344
 compulsory drug licensing in, 460–461
 patents in, 345
 poverty thesis in, 345–347
 treatment costs, annually, 344
- Gilmartin, Raymond, 13
- Gingrich, Newt, 15
- Global AIDS Fund, 349, 391
- globalization
 disease pandemics as result of, 370
 health care systems during, 291–292
- The Global Fund to fight AIDS,
 Tuberculosis and Malaria, 341
 Johnson & Johnson and, 33
 Merck Industries and, 33
 participants in, 33
 tropical disease research and, 32
 US contributions to, 341
- Goldkind, Sara, 18
- Good Clinical Practice: Consolidated
 Guidance*, 59
- Goodman, Kenneth, 270
- Gore, Al, 340
- Gorman, Michael, 259, 380, 382, 383
- Gorrie, Tom, 367
- government(s)
 drugs development reimbursement by,
 288–289
 DTCA policy and, 180–183
 ethics and, 109
 as funding source, 322
- in genomic research, 295–296
 individualized therapies and, policy
 development, 93–94
 moral issues and, 109–110
 pediatric research policy, 49
 stem cell research policy and, 109
- Grace, WR, 266
- GRAD (Genomic Research in the
 African Diaspora) Biobank, 91
- Grassley, Charles, 16
- GSK (GlaxoSmithKline), 274, 389
 antidepressant research by, 77
- Guidelines for Good Clinical Practice for
 Trials on Pharmaceutical Products.
See GCP
- Guillain Barré syndrome, 468
- Haiti
 HIV/AIDS in, 278–279
- Hale, G. Victoria, 11
- Hardin, Garrett, 267, 269
- Harris polls, 3
- Hay, Joel, 133, 134
- Hayes, Arthur Hull, 155
- health care systems. *See also* health care
 systems, private; health care systems,
 public
 access to, 227
 chronic care as part of, 376
 consumer involvement in, 171–172
 cost-benefit analysis for, 228, 230–231
 cost-effectiveness for, 228
 as delivery government role in, 283
 demand management for, 201–202
 DTCA and, 128–131, 169–170, 179
 elderly care as part of, 376
 expenditures for (US), 134, 225
 during globalization, 291–292
 government role in, 283
 information technologies for, 172, 294
 limit setting within, 206–207
 literature for (US), 232–234
 in The Netherlands, 200
 nontoxic treatments as part of, 294
 outpatient care within, 294–295
 patient's rights under, 171
 per capita spending, pharmaceuticals
 (international), 226
 pharmacy benefit management in,
 206–207

- prevention efforts of, 295
 public pension expenditures (by GDP), 241
 safety nets for, 376–377
 third party payer system and, 133–135
- health care systems, private
 QALY and, 229
- health care systems, public
 insurance under, 292–294
 Medicaid as part of, 292
 multi-stakeholder cooperation for, 367–368
 PAPs and, 292, 293
 Partnership for Prescription Assistance as part of, 292
 private enterprise and, 363–365, 466
 State Children’s Health Insurance Programs under, 292
- health literacy, 376
 for African Americans, 88
 consumer surveys and, 178
 “cultural competency” and, 88
 language as factor in, 87
 for minorities, 87–89
 patient informational practices and, 88
- health maintenance organizations. *See* HMOs
- Health Sector Assembly. *See* HSA
- Heller, Michael A, 269
- Helsinki Declaration of Ethical Principles for Medical Research Involving Human Subjects, 17, 37, 39, 40, 41, 42, 46, 64, 102, 409
 informed consent under, 197
 “Notes of Clarification” as part of, 39
 patient selection under, 70
 placebo controls and, 74
- HFE (Human Fertilization and Embryology) Act (UK), 119
- HHS (Health and Human Services), 61, 93
 Dickey Amendment and, 117
 rulemaking for, 117
- high blood pressure
 among African Americans, 84
- Hippocratic Oath, 22, 107, 131
- Hispanic Americans, 82
 antidepressants and, 80, 84
 belief systems for, 89
 pain medications for, 80
- HIV/AIDS (Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome), 1, 371
 activism and, 15, 301–306
 ADAP and, 310
 in Africa, 28, 273, 339, 347–348
 in Asia, 28
 AZT and, 270, 302, 304
 Bill and Melinda Gates Foundation and, 35
 in Botswana, 277
 clinical research participation and, for patients, 19
 clinical testing for, 93
 combination therapies for, 305, 348, 462
 “compassionate use” programs for, 25
 corporate collaborations and, 33–36
 didanosine for, 303, 304
 disease markers for, 304
 drug pricing for, 302
 “expanded access” programs for, 25
 Forum for Collaborative HIV Research, 298
 in Haiti, 278–279
 as international pandemic, 281, 452
 IP rights and, 268
 mother-to-child transmission, 222, 461
 new drug development for, 253
 patents system and, 253
 patient’s rights and, 104–105
 possible treatments for, 302
 poverty and, 338–339
 property rights and, 379–381
 protease inhibitors and, 305
 Rescue Principle for, 381–385
 in South Africa, 339
 in sub-Saharan Africa, 273, 452
 in Tanzania, 277–278, 279
 Triomune, 349
 US government funding for, 341–342
 vaccine development for, 274
 women and, 372
- HMOs (health maintenance organizations), 219
- HMS Salisbury (ship), 97
- Holt, Rush, 20
- Horwitz, Jerome, 270
- HSA (Health Sector Assembly), 375, 376
 members of, 375

- Hsieh, Nien-hê, 364
 Human Cloning Prohibition Act (US), 113
 Human Embryonic Stem Cell Registry, 121
 Human Fertilization and Embryology Act. *See* HFE
 Human Genome Project, 83, 91
 Human Immunodeficiency Virus. *See* HIV/AIDS
 human rights. *See* rights, human
 Hume, David, 261
 Huxley, Aldous, 115
 hypertension
 drug classes for, 139
 IAVI (International AIDS Vaccine Initiative), 357
 ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use), 37, 40
Clinical Investigation of Medicinal Products in the Pediatric Population
 in, 58, 59
 clinical trials and, 45
 funding sponsor obligations for, 45
Good Clinical Practice: Consolidated Guidance in, 59
 “minimal risks” guidelines, 73
 on pediatric research, 57, 68
 on placebo controls, 74
 Idänpään-Heikkilä, Juhana E, 17, 57
 Idris, Kamil, 265
 IEC (institutional ethics committee), 62
 IIPI (Intellectual Property Institute), 342–343, 459
 on drug access, 343
 Imitrex, 211
 pharmacy benefit management and, 211–212
 restrictions on, 214
 immunization program(s), 386–387
 National Immunization Days, 390
 in US, 386–387
 imports, drug
 health concerns as result of, 293–294
 under MMA, 239–240
 for pharmaceutical industries, 3
 US Congress and, 328
 in vitro fertilization. *See* IVF
 India
 IP rights in, 265–266, 268
 industries, biotech, 332–333
 industries, pharmaceutical
 AIDS activism and, funding for, 318
 biotech industries and, 332–333
 cost containment within, 236–239
 drug importation for, 3
 drug manufacturing for, 3
 drug pricing for, 3
 as funding source, 323
 “grand bargain” for, 1–2
 “innovation deficit” within, 30
 institutional partners for, 5
 IP within, 3
 literature about, 365
 Medicaid and, 3
 NGOs and, 5
 patents within, 10
 patient’s rights and, 3
 prescriptions drugs and, 3
 public image for, 3–4, 394–397
 sales representatives in, 148–149
 “silo mentality” in, 236
 infertility
 IVF and, 116
 influenza
 antiviral drugs for, 354
 Asian bird, 291
 “swine,” 468
 vaccines for, 256–257, 352–354
 WHO and, 291
 influenza vaccines. *See* vaccines, influenza
 information, medical sources
 for general medications, 147–148
 Internet, 198
 sales representatives as, 148
 in UK, medical, 198–199
 information, patient, 199–200. *See also*
 informed consent
 direct-to-consumer, 202–203
 DTCA and, 202
 economic impacts of, 200–201
 “*Informed Patient*” Project and, 130, 196, 198, 204–205
 NHS Direct (UK) and, 202
 from physicians, 148

- informed consent, 44–45, 197–199
 age for, 103
 for children, 43–44
 in China, 44
 in clinical trials, 39
 cultural belief systems and, 103
 under Helsinki Declaration of Ethical Principles for Medical Research Involving Human Subjects, 197
 husband-wife relationships and, 44
 in International Ethical Guidelines for Biomedical Research Involving Human Subjects, 44
 in non-therapeutic clinical research, 42–43
 The Nuremberg Code of 1947 and, 44
 under state-controlled systems, 197
 in UK, 197
 “Informed Patient” Project, 130, 196, 198, 204–205
- innovations. *See also* drugs, new; patents
 in France, 333–334
 in Germany, 333
 incentives for, 243–244, 288
 “off-label” uses and, 290
 under Orphan Drug Act, 289
 recognition for, 287–290
 in UK, 333
 in US, 333
- Institute for OneWorld Health, 11, 381, 400, 401
- Institute of Medicine, 16
- institutional ethics committee. *See* IEC
- Institutional Review Boards. *See* IRBs
- insurance
 formularies and, 147
- intellectual property. *See* IP
- Intellectual Property Institute. *See* IPI
- International AIDS Vaccine Initiative.
See IAVI
- International Committee of Medical Journal Editors, 78
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. *See* ICH
- International Ethical Guidelines for Biomedical Research Involving Human Subjects, 37, 41, 42
 informed consent as part of, 44
- International Society for Pharmacoeconomics and Outcomes Research, 237
- Internet
 drug sales and, 293
 medical information and, 198
- Invermectin
 Merck Industries and, 12
- Investing in Health*, 345
- IOM (Institute of Medicine), 69, 355, 356, 421
 “minimal risks” and, recommendations, 71
- IP (intellectual property)
 alliance models for, 275–280
 in Brazil, 268
 challenges to, 260, 265–268
 corporate investments and, 265
 development of, 260
 HIV/AIDS and, 268
 human rights and, 261–280
 in India, 265–266, 268
 industries, pharmaceutical, and, 3
 Jefferson, Thomas, and, 262
 Locke, John, and, 262, 263
 moral imagination and, 275–276
 multiple perspectives system for, 276–277
 overprotection of, 269
 for Pfizer Pharmaceuticals, 268
 privatization of, 269
 The Rescue Principle and, 385
 rights-based defenses of, 262–263
 in sub-Saharan Africa, 346
 in “third world” countries, 257–259, 265
 time limited claims for, 262, 272
 in US, 267–268, 340
 utilitarian defenses of, 264–265
 WIPO and, 265
 WTO rules for, 346
- IRBs (Institutional Review Boards), 58, 93, 398
 for pediatric research, 60
 for placebo-controlled clinical trials, 63
- Ireland
 stem cell research in, 119
- Israel
 stem cell research in, 120
- Italy
 stem cell research in, 119

- IVF (in vitro fertilization), 115, 428
 American Society for Reproductive
 Medicine and, 116
 FET, 428
 GIFT, 428
 infertility and, 116
 Society for Assisted Reproductive
 Technology and, 116
 stem cell research and, 115
 “test tube babies” from, 115
 TET, 428
 in US, 116
 US government restrictions on, 118
 ZIFT, 428
- Japan
 stem cell research in, 120
- Jefferson, Thomas, 261, 280
 IP rights and, 262
 on patent protection, 261
- Jews, Ashkenazi
 antidepressants and, 85
- Johnson & Johnson
 The Global Fund to fight AIDS,
 Tuberculosis and Malaria and, 33
- Joint United Nations Programme on
 HIV/AIDS. *See* UNAIDS
- Journal of the American Medical
 Association, 16
- Kefauver-Harris Amendments, 14, 334
 drug safety under, 12
 FDCA and, 49
- Kelly, Pat, 4
- Kenya
 antiretrovirals in, 347
- Kessler, David, 15
- Kipling, Rudyard, 295
- Kordel v. United States*, 186
 drug labeling and, 187
- Koski, Greg, 368, 381
- Kremer, Michael, 244
- labeling, drugs
 “black box,” 13
 under FDCA, 186–187
 intended uses and, 438
 interaction warnings for, 91
 in *Kordel v. United States*, 187
 pediatric rules for, 50
 regulations for, 49, 438
- Laetrile, 15
- The Lancet*, 16
- language
 clinical trials and, as barrier, 19
 health literacy and, 87
 informed consent and, as factor for,
 103
- LDC (least-developed countries),
 273. *See also* “third world” nations
 drug distribution in, 279
 least-developed countries. *See* LDC
- Lee, S, 82
- Leeper, Mary Ann, 277
- licensing, drugs
 clinical research and, 22
 compulsory, 338, 460–461
 in South Africa, 339
- life expectancy rates
 international increase in, 236
- “lifestyle” drug(s), 127, 253. *See also*
 drugs, prescription
 MUSE, 163
 Viagra as, 217–218
- Lind, James, 97, 108
- Lichtenberg, Frank, 235
- Locke, John, 260, 261
 on IP rights, 262, 263
- Luce, Bryan, 222
- Macroeconomics and Public Health*
 (WHO), 342
- Magnetic Resonance Imaging. *See*
 MRI
- Maimonides
 medical oaths and, 107
- major depressive disorder. *See* MDD
- malaria. *See also* diseases, tropical
 drug development for, 388–389
 institutional partnerships’ research for,
 11
 Malarone and, 388
 research for, 10, 11
- Malarone, 388
- managed care, 219
- manufacturing, drugs
 for pharmaceutical industries, 3
- “March of Dimes,” 386
- marketing. *See* DTCA
- Maxwell, John, 395
- McClellan, Mark, 254
- McKinnell, Hank, 254

- MDD (major depressive disorder), 76
 MHRA and, 76
 Mectizan Donation Program, 372, 388, 389
 WHO and, 372
 Medicaid. *See also* health care systems, public
 benefit allocations under, 209
 minorities and, 82, 87
 per capita spending (c. 1970), 225
 pharmaceutical industries and, 3
 reimbursement under, 440
 medical intervention outcomes
 ‘pharmacoeconomic league tables’ and, 230
 QALY and, 228
 medical technologies, 233
 informational, 294
The Medical Letter on Drugs and Therapeutics, 147
 Medicare
 benefit allocations under, 209
 co-payment requirements for, 289
 drug benefit for, 133
 minorities and, 82, 87
 MMA, 239–240
 “off-label” usage and, 132
 per capita spending (c. 1970), 225
 reform, 328
 medications, alternative, 144–145. *See also* alternative treatment(s)
 medications, brand name. *See also* drugs, prescription
 generic v., 140–141
 medications, general. *See also* drugs, prescription
 American College of Physicians recommendations for, 145
 controlled substances and, 146
 DTCA and, influence on, 175–176
 DTCA for, 144
 ethnicity and, 80, 85
 FDA and, 140
 free, 148
 generic v. brand name, 140–141
 information sources for, 147–148
 Nexium, 142
 OTC, 134, 141, 142
 patient requests for, 144
 prescription v. OTC, 141–142
 side effects of, 146–147
 medications, generic. *See also* drugs, prescription
 brand name v., 140–141
 Medicines and Healthcare Products Regulatory Agency. *See* MHRA
 Medicines and Related Substances Act (South Africa), 339, 379
 Médecins Sans Frontières (Doctors Without Borders), 259, 349
 MEDWATCH, 54
 Merck, George W, 12, 368, 452
 Merck Industries, 11, 13, 358, 388, 391
 The Global Fund to fight AIDS, Tuberculosis and Malaria and, 33
 Invermectin and, 12
 Mectizan Donation Program, 372
 mission for, 452
 stock prices for, 16
 Vioxx and, 13–14
 Mesenchymal Stem cells. *See* MSC
 MHRA (Medicines and Healthcare Products Regulatory Agency)
 MDD and, 76
 “minimal risks”
 CIOMS guidelines for, 71, 73
 for drug therapies, 22
 ICH guidelines for, 73
 IOM recommendations for, 71
 National Commission definition for, 71, 73
 for pediatric research, 59–62, 71, 72–73
 for placebo-controlled clinical trials, 65
 variability of, 71
 minorities. *See also* African Americans; Asians; Hispanic Americans; Jews, Ashkenazi
 alternative medicine and, 90
 cancer therapies and, 80
 clinical testing and, 92–93
 drug access for, non-traditional, 89–90
 drug toxicity and, 81
 health literacy for, 87–89
 individualized therapies and, 81–83
 Medicaid and, 82, 87
 Medicare, 82, 87
 misbranding
 under FDCA, 161, 184
 labeling and, 187
 new drugs and, 185–186

- MMA (Medicare Modernization Act) (US), 239–240
 drug importation under, 239–240
 managed care expansion under, 240
 Modernization Act of 1997, 18
 moral imagination, 275–276
 morbidity rates
 for vaccine-preventable diseases, 356
 mortality rates
 from Vioxx, 16
 Motrin, 141
 MRI (Magnetic Resonance Imaging), 61
 MSC (Mesenchymal Stem cells), 427
 multiple perspectives system (IP rights), 276–277
 Bill and Melinda Gates Foundation and, 277
 Merck and, 277
 NGO funding for, 277
 WHO and, 279
 Murphy, Dianne, 18, 396
 MUSE (Urethral Suppository)
 FDA and, 163
 usage risks for, 163
- National Ambulatory Medical Care Survey, 177
 National Childhood Vaccine Injury Act, 449
 National Cholesterol Education Program. *See* NCEP
 National Commission, 74
 “minimal risks” definition for, 71, 73
 National Immunization Days, 390
 National Institutes of Health. *See* NIH
 National Medical Association, 19
 NCEP (National Cholesterol Education Program), 138
 Neemix, 266, 270
 Nelson, Robert, 18
 Nelson, Skip, 396
 The Netherlands
 health care costs in, 200
 Neurontin, 132, 133, 191
 “off-label” usage for, 192, 431
 Nevirapine, 461
 New Zealand
 clinical trials in, 102
 IRBs in, 102
The New York Times, 3, 291
 Nexium, 142
- NGOs (non-governmental organizations)
 Axios Foundation, 277
 multiple perspectives system funding by, 277
 pharmaceutical industries and, 5
 NHRPAC (National Human Research Protection Advisory Committee)
 pediatric research and, 60
 NHS Direct (UK), 202
 NIH (National Institutes of Health), 92
 AIDS activism and, 308
 AZT and, 270
 Human Embryonic Stem Cell Registry and, 121
 research budget for (2004), 234
 rulemaking for, 117
 Nixon, Richard, 114
 NOAH (Nurturing Orphans of Aids for Humanity) Ark project, 391
 Noah, Barbara, 87, 92, 93
 Noble, Gary, 257
 non-governmental organizations. *See* NGOs
 Norway
 antiretrovirals in, 347
 The Nuremberg Code of 1947, 101
 clinical trials and, 38
 Doctors’ Trial and, 38
 informed consent and, 44
 ten principles for, 38–39
 Nurturing Orphans of Aids for Humanity. *See* NOAH
 nutrition
 individualized therapies and, 86
- oaths, medical, 107–108. *See also* ethics;
 Hippocratic Oath
 Hippocratic, 22, 107, 131
 Maimonides and, 107
 Office of Pediatric Therapeutics, 69
 Office of Technology Assessment. *See* OTA
 “off-label” uses (prescription drugs)
 dosing for, 69, 132
 under FCA, 191
 FDA approval for, 187, 193
 under FDCA, 185, 187
 under First Amendment, 188–191, 193
 in *Franklin v. Parke-Davis*, 191
 future applications for, 193–195
 innovations and, 290

- Medicare and, 132
 for Neurontin, 192, 431
 Parke-Davis and, 132
 promotion for, 184, 187–188, 438
 old age dependency ratios, 242
onchocerciasis. *See* River Blindness
 Orphan Drug Act, 30, 289
 OTA (Office of Technology Assessment),
 114, 123
 OTCs (over-the-counter medications).
See also medications, general
 aspirin, 150–152
 Claritin, 141
 drug modifications and, 142
 FDA specifications for, 141–142
 Motrin, 141
 Prilosec, 141
 third party payer system and, 134, 141
 Zantac, 141
 Ottesen, Eric, 389
 outpatient care, 294–295
 over-the-counter medicines. *See* OTCs
 Oxfam, 259
 OxyContin, 162–163
 indicated use violations for, 163
 usage risks for, 163
 PAC (Pediatric Advisory Committee),
 69
 PAPs (Patient Assistance Programs)
 in public health care systems, 292, 293
 Parke-Davis
Franklin v. Parke-Davis and, 191–193
 Neurontin and, 132, 133, 191
 “off-label” drug uses and, 132
 Parkinson’s Disease, 15
 paroxetine, 76
 “The Participation of Underrepresented
 Minorities in Clinical Research”
 (Noah), 87
 Partnership for Prescription Assistance,
 292
 patent law(s), 337–339
Brenner v. Manson, 337
 development of, 262
 drug pricing and, 140
 patents, 242, 331, 337–338
 for DNA sequences, 269
 for Enola beans, 266
 generic drugs v., 243
 in Gillespie-White/Attaran study, 345
 HIV/AIDS and, 253
 for Jefferson, Thomas, 261
 legal protections for, 140, 262, 337–339
 market competition and, 242
 within pharmaceutical industries, 10
 protection for (US), 227, 350
 in public domain, 244–246
 reward systems for, 245
 social benefits from, 448–449
 in “third world” nations, 258
 WHO and, 244
 Patient Assistance Programs. *See* PAPs
 “Patient Package Inserts,” 155
 patient selection
 EU Directive on Clinical Trials and, 70
 GCP and, 70
 under Helsinki Declaration of Ethical
 Principles for Medical Research
 Involving Human Subjects, 70
 for pediatric research, 70–71
 patient’s rights. *See* rights, patient’s
 Paxil, 54, 65
 adverse reactions to, 55
 efficacy trials for, 55
 PC (Pediatric Committee), 70
 EMEA and, 70
Pearson v. Shalala, 190
 Pediatric Advisory Committee. *See* PAC
 Pediatric Committee. *See* PC
 pediatric research. *See* research, pediatric
 Pediatric Research Equity Act. *See*
 PREA
 Pediatric Rule, 50
 pediatrics. *See also* research, pediatric
 AAP and, 48
 labeling rules, 50
 “off-label” medication use in, 69
 Penicillin, 27
 Pfizer Pharmaceuticals, 358
 IP rights for, 268
 pharmaceutical industries. *See* industries,
 pharmaceutical
 Pharmaceutical Manufacturers
 Association of America, 133
 pharmaceutical research. *See* research,
 clinical
 Pharmaceutical Research and
 Manufacturers of America. *See*
 PhRMA
 pharmacies
 industrialization of, 26

- 'pharmacoeconomic league tables,' 230, 232
- pharmacogenetics, 83. *See also* genetics
- pharmacogenomics, 83
- pharmacology
 biochemistry and, 149–150
 etymology of, 136
- pharmacovigilance
 BPCA on, 54
 in pediatric research, 54–56
- pharmacy benefit management
 accountability under, 208
 decision revision under, 208
 drug allocation as part of, 208–209
 ethical template for, 209–222
 Imitrex and, 211–212
 Medicaid and, 209
 Medicare and, 209
 in public health care, 206–207
- Philippines, the
 stem cell research in, 120
- PhRMA (Pharmaceutical Research and Manufacturers of America), 77, 311, 340, 366
- physician detailing, 128, 131, 154, 181–182. *See also* sales, drug
 “academic,” 181
 aids for, 154
 expenditures for, 131
- physician package insert. *See* PI
- physicians
 clinical research and, role in, 26–27
 detailing for, 128
 DTCA and, influence on, 175
 mistrust of, 139
 “patient-centered” practices for, 171
 sales representatives and, 148
Physician's Desk Reference, 50
 PI (physician package insert), 157
 placebo-controlled clinical trials. *See* trials, clinical (placebo-controlled)
- polio vaccine. *See* vaccine, polio
- polls
 Gallup, 4
 Harris, 3
- Polybius (Roman historian), 386
- Portugal
 stem cell research in, 119
- poverty, 342–344
 in Gillespie-White/Attaran study, 345–347
 HIV/AIDS and, 338–339
- PREA (Pediatric Research Equity Act), 50, 69
- FDA and, 69
- PAC and, 69
- requirements for, 51
- price controls, 333
 in Canada, 327
 in EU, 327
 in UK, 327
- pricing, drugs
 conflicts over, 311–316
 “freezes” for, 310
 for HIV/AIDS, 302
 market-based, 331
 patent law (US) and, 140
 for pharmaceutical industries, 3
- Prilosec, 141
- priority principle, 442
- Proctor, Larry, 266
 Enola beans and, 266
- profit maximization
 in clinical research, 9–12
 free market systems and, 10
- Prograf, 164
- Project Inform, 306
- promotions, drug (prescription). *See also* sales, drug
 for accelerated approval products, 164–165
 DTC, 165
 FDA violations for, 162–164
 FDCA guidelines for, 159, 166, 167
 under First Amendment, 184
 introductory campaigns, 165
 “off-label” use and, 184, 187–188, 438
 regulation of, 159–162, 167
 samples as part of, 158
 statutory framework for, 185–188
 types of, 158–159, 164–165
 US expenditures for (2003), 157–158
- Prontosil, 27
- property rights. *See* rights, property
- protease inhibitors
 HIV/AIDS and, 305
- public domain
 patents in, 244–246

- publications
 of clinical trials, 46–47
- QALY (quality adjusted life years), 228, 229
 application limitations of, 231
 cost-effective analysis and, 229, 230
 costs per year (US), 229
 private health care and, 229
 quality adjusted life years. *See* QALY
 “qui tam” suits, 191
- race-based drug therapies, 94–96
 for African Americans, 94
 BiDil and, 95
 FDA and, 95
- Rand, Ayn, 263
- Rand Health Care Appropriateness
 Methodology Research Program,
 232, 240
- randomized clinical trials. *See* trials,
 clinical (randomized)
- rare indications. *See* diseases, rare
- Ratzan, Scott, 130
- R&D (research and development), 228.
See also drugs, new
 approval times for, 296–298
 for aspirin, 151
 for AZT, 270, 302, 304
 for didanosine, 303, 304
 disease markers in, 297
 EU pharmaceutical industry
 expenditures, 235
 for HIV/AIDS, 253
 for Prontosil, 27
 of protease inhibitors, 305
 technological risks during, 330
 US pharmaceutical industry
 expenditures (2003), 234
- recalls, drug, 25
 in UK, 25
 in US, 25–26
- regulations, drug
 APA and, 116
 costs for, 15
 for efficacy, 15
 for pediatric research, 49–52
 for promotional materials, 161–162
 for safety, 15
 in US, 116–118
- Reinhardt, Uwe, 208
- Related Agencies Appropriations Act
 SCNT under, 112
 stem cell research and, 112, 427
 reminder advertisements, 156–157. *See*
also DTCA
 “brief summary” as part of, 156
 reproductive cloning, 111
 SCNT v., 111, 115
- The Rescue Principle
 HIV/AIDS and, 381–385
 IP rights and, 385
- research and development. *See* R&D
- research, clinical (non-therapeutic)
 ethical guidelines for, 41–44
 guidelines for, 414–415
 informed consent as part of, 42–43
 Phase I studies for, 42
 for vulnerable groups, 43–44
- research, clinical (therapeutic), 36
 children and, 17–18
 for common diseases, 28
 costs for, 27–28
 drug licensing and, 22
 economic pressures for, 26
 ethical guidelines for, 9, 26–31, 38–41
 for malaria, 10
 medical ethics in, 36
 participation in, 19–20
 patient’s rights in, 9, 16–20
 physician’s role in, 26–27
 profit maximization in, 9–12
 for rare diseases, 29
 scientific ethics in, 36
 stem cell, 9
 Tuskegee syphilis study, 17
- research, genetic
 DNA arrays as part of, 91
 for drug therapies, 91–92
 GRAD and, 91
- research, genomic, 295–296
 FDA and, 295
 government role in, 295–296
- research participation (clinical)
 for HIV/AIDS, 19
 language/cultural barriers to, 19
 for minorities, 19, 20
 Tuskegee syphilis study and, 19
- research, pediatric
 AAP and, 48
 ADME studies and, 48
 adult studies’ extrapolations in, 56

- research, pediatric (*cont.*)
 adverse effects during, undefined, 53
 CFR on, 57, 59
 CIOMS on, 57, 68
 clinical trials for, 48, 51
 developmental behavior during, 53–54, 56, 290
 “direct benefit” in, 73–74
 dosing calculations in, 48
 ethical guidelines for, 56–62
 EU Directive on Clinical Trials and, 68
 as exploitation, 78
 FDA and, 48
 government policy for, 49
 ICH on, 57, 68
 ineffective dosing in, 52–53
 ineffective therapies during, 52
 IRBs for, 60
 legislative approaches to, 69–70
 for MDD, 76
 minimal risks for, 59–62, 71, 72–73
 NHRPAC and, 60
 for paroxetine, 76
 patient condition for, 72–73
 patient selection for, 70–71
 Pediatric Rule for, 50
 pharmacovigilance in, 54–56
 placebo-controlled clinical trials for, 63–65, 74–75
 post-approval studies as part of, 56
 public results of, 51
 queries for, 58
 randomized clinical trials for, 62–65
 regulations for, 49–52
 “sentinel canaries,” 49
 as social contract, 75–78
 variability in, 56
- research, stem cell, 20, 110–114
 abortion policies and, 20
 Alzheimer’s Disease and, 20
 ART and, 115
 in Australia, 120
 in Austria, 119
 in Canada, 120
 in China, 120
 Dickey Amendment (US) and, 111, 121
 foreign regulations for, 118–121
 in France, 119
 in Germany, 119
 HFE Act (UK) for, 119
 Human Cloning Prohibition Act and, 113
 in Ireland, 119
 in Israel, 120
 in Italy, 119
 IVF and, 115
 in Japan, 120
 for pharmaceutical industries, 9
 in The Philippines, 120
 in Portugal, 119
 private organizations and, 121
 Related Agencies Appropriations Act and, 112
 SCNT as part of, 110
 in Spain, 119
 in Sweden, 119
 in UK, 119–120
 US government policies for, 109, 118, 122
 US law and, 111–114
- rights, human, 261
 IP as part of, 261–280
- rights, patient’s, 104–107
 in clinical research, 9, 16–20
 HIV/AIDS research and, 104–105
 pharmaceutical industries and, 3
 under public health care, 171
 researcher trust and, 101, 104
 trial participation as part of, 97–100, 105–106
- rights, property
 HIV/AIDS and, 379–381
- risk management, 285–287
 in clinical trials, 285
 FDA approval and, 285
- risk-benefit ratios
 for drug therapies, 22
 for prescription drugs (antibiotic), 137
 for prescription drugs (general), 137
- River Blindness, 11–12, 388, 469
 cause of, 469
 symptoms of, 11
- Rogaine
 DTCA and, 171
 Upjohn and, 171
- Rosenthal, Meredith, 129
- Rotary International, 389–390
- rulemaking, 117. *See also* regulations,
 drug
 for HHS, 117
 “informal,” 117
 for NIH, 117

- Sabin, James, 135
 SACHRP (Secretary's Advisory Committee for Human Research Protection), 60
 Sachs, Jeffrey, 349
 safety, drugs, 12–16
 antidepressants and, 13
 Fen-Phen and, 13
 Kefauver-Harris Amendments and, 12
 regulations for, 15
 thalidomide and, 13
 sales, drug
 “business stealing” as part of, 173
 DTCA and, influence on, 173
 international share (for US), 227
 Internet and, 293
 “sales calls” for, 154
 sales representatives. *See also* physician detailing
 free medications and, 148
 honoraria for, 148
 patient information from, 148
 in pharmaceutical industries, 148–149
 physician information from, 148
 teaching materials and, 148
 Salk, Jonas, 372
 Scanlon, TM, 382
Science, 267
 SCNT (Somatic Cell Nuclear Transfer), 110, 111
 genetic information from, 111
 grafting as part of, 111
 under Related Agencies Appropriations Act, 112
 reproductive cloning v., 111, 115
Second Treatise on Government (Locke), 260
 Secretary's Advisory Committee for Human Research Protection. *See* SACHRP
 Section 301 watch list, 339–340
 South Africa and, 339
 trade sanctions under, 339
 selective serotonin reuptake inhibitors. *See* SSRI
 “A Sensible Compromise on Viagra,” 219
 “sentinel canaries,” 49
 Shirkey, H, 49
 side effects
 of AZT, 303
 in clinical trials, 468
 of general medications, 146–147
 “silo mentality,” 236
 Singleton, Peter, 130
 sixth research framework program. *See* FP6
 small pox, 355, 387
 Smith, Adam, 261
 smoking
 African Americans and, 86
 bupropion and, 86
 individualized therapies and, 86–87
 Society for Assisted Reproductive Technology, 116
 Somatic Cell Nuclear Transfer. *See* SCNT
 South Africa
 compulsory drug licensing in, 339
 HIV/AIDS in, 339
 Medicines and Related Substances Act, 339, 379
 on Section 301 watch list, 339
 South Korea
 cloning limits in, 120
 Spain
 stem cell research in, 119
 SSRI (selective serotonin reuptake inhibitors), 219–221
 antidepressants v., 219, 287
 children and, 396
 data-suppression for, 398
 State Children's Health Insurance Programs, 292
 stem cell research. *See* research, stem cell
 stem cells, 110. *See also* research, stem cell
 cell
 adult, 111
 EG, 121
 ES, 110, 121
 MSC, 427
 steroids
 placebo-controlled clinical trials for, 74–75
 Strategic Defense Initiative (US), 114
 subspecialty care, 146
 suicidal ideation
 antidepressants and, 77
 Sulfanilamide, 49
 Superfund (US), 114
 “superior good,” 443

- surveys, consumers
 for DTCA, 153, 172, 173–175, 177
 health literacy and, 178
- Sweden
 stem cell research in, 119
- Tanzania
 Abbott Laboratories Fund in, 277
 antiretrovirals in, 347
 HIV/AIDS in, 277–278, 279
- Taurel, Sidney, 255
- Teagarden, Russell, 135
- Tenormin, 143
- “test tube babies,” 115
- testing, clinical
 African Americans and, 93
 FDA and, 92
 for HIV/AIDS, 93
 minorities and, 92–93
 NIH and, 92
- TET (tubal embryo transfer), 428
- Thalidomide, 13, 49, 393
 children and, 17
- therapeutic cloning. *See* SCNT
- therapies, cancer
 minorities and, 80
- therapies, combination
 for HIV/AIDS, 305, 348, 462
 Triomune, 349
- therapies, drug
 genetic research for, 91–92
 medical ethics and, 21–22
 race-based, 94–96
 risk-benefit ratios for, 22
- therapies, individualized, 81–92. *See also*
 therapies, drug
 cultural practices and, 89–91
 drug dosage in, 94
 environmental factors in, 86–87
 genetic factors within, 83–85
 government policy for, 93–94
 minorities and, 81–83
 non-genetic factors in, 85–91
 nutrition and, 86
 polymorphism and, 83
 smoking-related activities and, 86–87
There's No Such Thing as Business Ethics
 (Maxwell), 395
- third party payer system
 formularies and, 147
- OTCs and, 134, 141
 public health care and, 133–135
- “third world” nations
 IP rights in, 257–259, 265
 patent protections in, 258
- Thompson, Tommy, 341
- Thompson v. Western States Medical Center*, 190
- TNF α (tumour necrosis factor), 24
- Toprol XL, 143
- Trade Act (US), 457
- “tragedy of the commons,” 267, 268–272
- trials, clinical, 24
 abuses during, 426
 candidate selection during, 330
 comparative pharmacokinetic studies
 and, 38
 comparator products in, 46
 didanosine in, 304
 disclosure as part of, 319–320
 double-blind, 23, 24
 ethical review committees and, 45
 false data in, 315
 fixed-dose combination drugs and, 38
 foreign, 98–99
 funding sources for, 322–324
 guiding principles for, 318–324
 ICH and, 45
 informed consent as part of, 39
 international documents for, 39
 for new drugs, 38
 in New Zealand, 102
 The Nuremberg Code of 1947 and, 38
 patient's rights and, 97–100, 105–106
 pediatric research and, 48, 51
 phases for, 46
 placebo-controlled, 63–65, 407, 416
 publication of, 46–47
 randomized (pediatric), 39
 risk management in, 285
 side effects during, 468
 sponsor obligations for, 45–46
 structured communication during,
 320–322
- trials, clinical (placebo-controlled),
 63–65, 407, 416
- Helsinki Declaration of Ethical
 Principles for Medical Research
 Involving Human Subjects and, 74
- ICH and, 74
- IRBs and, 63

- mother-to-child HIV transmission, 222
 for pediatric research, 63–65, 74–75
 pediatric research and, 74–75
 priority principle in, 442
 rationing for, 442
 risks for, 65
 for steroids, 74–75
 WMA and, 64, 74
 trials, clinical (randomized)
 clinical equipoise in, 62–63
 DMC in, 62
 IEC input on, 62
 for pediatric research, 62–65
 Triomune, 349
 TRIPS agreement, 343, 346, 350, 351, 452.
 See also Doha Declaration on
 TRIPS and Public Health
 tropical indications. *See* diseases, tropical
 Trovan, 143
 tubal embryo transfer. *See* TET
 tumour necrosis factor. *See* TNF α
 Tuskegee syphilis study, 17
 African Americans as part of, 19, 101
 AP and, 101

 UK (United Kingdom)
 cost guidelines in (new drugs), 238
 drug price controls in, 327
 drug recalls in, 25
 informed consent in, 197
 innovation output in, 333
 medical information in, 198–199
 new drug launches in, 25
 NHS Direct in, 202
 Stem Cell Bank in, 119
 stem cell research in, 119–120
 UK Stem Cell Bank, 119
 UN International Covenant on Civil and
 Political Rights (1966), 39
 UNAIDS (Joint United Nations
 Programme on HIV/AIDS), 40
 “Ethical Considerations in HIV
 Preventive Vaccine Research,” 40
 Universal Declaration of Human Rights
 (1948), 40
 Upjohn, 171
 US (United States)
 AMCP in, 238
 anthrax in, 267
 Clean Air Act, 114
 cloning restrictions in, 118
 Contract With America in, 114
 cost per QALY in, 229
 Dickey Amendment in, 111
 drug recalls in, 25–26
 Energy Security Act, 114
 Foreign Assistance Act, 114
 The Global Fund to fight AIDS,
 Tuberculosis and Malaria and,
 contributions to, 341
 healthcare expenditures in (2002), 134,
 225
 healthcare literature in, 232–234
 HIV/AIDS funding in, 341–342
 Human Cloning Prohibition Act, 113
 immunization program in, 386–387
 innovation output in, 333
 IP rights in, 267–268, 340
 IVF in, 116, 118
 MMA in, 239–240
 new drug launches in, 25
 Orphan Drug Act, 289
 Patent Office, 280
 patent protection in, 227, 350
 prescription drug sales, international
 share, 227
 prescription drug sales within (2003),
 153, 174, 226
 Public Health Service, 228
 regulation setting in, 116–118
 stem cell research in, government
 policies for (by state), 118
 stem cell research in, government
 policies for (general), 109, 122
 stem cell research in, laws for, 111–114
 Strategic Defense Initiative in, 114
 Superfund in, 114
 Trade Act in, 457
 Veteran’s Health Care Act, 288
 US Patent Office, 280
 US Trade Representative reports. *See*
 USTR
 USTR (US Trade Representative)
 reports, 339, 457
 Section 301 watch list in, 339

 vaccine development centers. *See* VDCs
 Vaccine Injury Compensation Program.
 See VICP
 vaccine, polio, 372, 386
 Rotary International and, 389–390
 Salk, Jonas, and, 372

- vaccines, 355–356. *See also* vaccine, polio;
 vaccines, HIV/AIDS; vaccines,
 influenza
 childhood, 231–232, 355, 446
 Childhood Immunization Initiative,
 256
 FDA and, 256
 future applications for, 354
 for HIV/AIDS, 274, 356–360
 influenza, 256–257, 352–354
 morbidity rates and, 356
 under National Childhood Vaccine
 Injury Act, 449
 needles and, 387
 production process for, 256
 public funds for, 355
 shortages, 256, 449
 small pox, 355
 VICP and, 352
 vaccines, HIV/AIDS, 356–360
 development of, 274
 VDCs and, 357
 vaccines, influenza, 256–257, 352–353, 354
 delivery systems for, 353
 demands for, 353
 discarded, 352
 Vagelos, Roy, 1, 4, 11, 399
 VDCs (vaccine development centers),
 357
 venlafaxine, 77
 Veterans' Health Care Act, 288
 Viagra, 213, 217–219
 FDA approval for, 217
 as “lifestyle” drug, 217–218
 “off-label” uses for
 VICP (Vaccine Injury Compensation
 Program), 352
 Viiox, 13–14, 15, 134
 “Dodge Ball,” 14
 FDA and, 16
 mortality rates from, 16
- Washington Legal Foundation. *See* WLF
Washington Legal Foundation v.
Friedman, 439
Washington Legal Foundation v. Henney,
 439
- The Washington Post*, 375
 Weldon, Dave, 113
 Weldon, William, 251, 380, 393, 399
 Werhane, Patricia, 259, 380, 382, 383
 WHO (World Health Organization), 17,
 236, 339, 387, 389, 452
 Asian bird influenza and, 291
 Collaborating Centers for Influenza,
 353
 funding sponsor obligations for, 45
 GCP and, 37, 40, 43
 Mectizan Donation Program and, 372
 multiple perspectives system and, 279
 patents and, 244
 tropical diseases and, 31
 WIPO (World Intellectual Property
 Organization), 265
 WLF (Washington Legal Foundation)
 Commercial Speech Doctrine and,
 189–190
 FDA guidance documents and, 189
 First Amendment case law and,
 190–191
 WMA (World Medical Association), 17,
 102
 Helsinki Declaration of Ethical
 Principles for Medical Research
 Involving Human Subjects and, 17,
 37, 39, 40, 41, 42
 on placebo-controlled clinical trials,
 64
- women
 HIV/AIDS and, 372
 World Health Organization. *See* WHO
 World Intellectual Property
 Organization. *See* WIPO
 World Medical Association. *See* WMA
 World Trade Organization. *See* WTO
 WTO (World Trade Organization), 258
 Doha Declaration and, 258
 IP rules for, 346
- Zantac, 141
 ZIFT (zygote intrafallopian transfer),
 428
 Zolofit, 54
 zygote intrafallopian transfer. *See* ZIFT